AIM
IMMU

Aigen Investment Management’s Immunomedics Inc IMMU Stock Holding History

Aigen Investment Management’s Portfolio IMMU Stock Details IMMU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-260
Closed -$6K – 1698
2019
Q4 		$6K Buy
+260
New +$4.59K ﹤0.01% 1002

Other funds holding IMMU

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Aigen Investment Management's IMMU Position: Q1 2020 in Review

Aigen Investment Management sold out of Immunomedics Inc (IMMU) in Q1 2020, closing a stake of 260 shares — an estimated $6K sold.

Aigen Investment Management first reported a position in IMMU in Q4 2019 and held it in 1 quarter. The position peaked at $6K in Q4 2019. 220 funds tracked by Wall St. Rank hold IMMU as of Q1 2020.

  • Aigen Investment Management reported no remaining Immunomedics Inc position as of Q1 2020 after selling out during the quarter.
  • Aigen Investment Management sold 260 Immunomedics Inc shares in Q1 2020, an estimated $6K.
  • Aigen Investment Management first reported a position in Immunomedics Inc in Q4 2019 and held it in 1 quarter.
  • Aigen Investment Management's Immunomedics Inc position peaked at $6K in Q4 2019.
  • 220 funds tracked by Wall St. Rank held Immunomedics Inc as of Q1 2020.

Based on Aigen Investment Management's 13F filing for Q1 2020, filed 8 May 2020.